2023 World Conference on Lung Cancer (Posters)-EP14.02. Neoadjuvant Immune Checkpoint Inhibitor-Based Therapy Followed by Resection for Locally Advanced Thymic Malignancies

EP14.02. Neoadjuvant Immune Checkpoint Inhibitor-Based Therapy Followed by Resection for Locally Advanced Thymic Malignancies - PDF(Abstract)

Back to course

Pdf Summary

This study explores the use of neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in patients with locally advanced thymic malignancies. The authors note that while second-line immunotherapy has shown promise in treating advanced thymic tumors, the use of ICI-based therapy in the neoadjuvant setting has not been well explored. <br /><br />The data for this study was obtained from a database of patients with potentially unresectable thymic malignancies who underwent surgical resection after receiving neoadjuvant therapy containing ICI, chemotherapy, and/or radiotherapy. The primary outcome measured was objective response rate according to the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Secondary outcomes included complete resection rate, perioperative outcomes, and progression-free survival.<br /><br />A total of 12 patients with thymic malignancies were included in the study, including thymomas, thymic carcinomas, and neuroendocrine thymic tumors. In patients with thymic carcinoma, the objective response rate was 57.1% in the first-line group and 50% in the second-line group. However, no patients with thymoma or neuroendocrine thymic tumors had objective responses to ICI-based therapy. The overall rate of complete resection was 66.7%, with a higher rate observed in patients who had a partial response to therapy. Postoperative complications occurred in 16.7% of patients, and one patient died after surgery. The median progression-free survival was 17 months, with a 1-year progression-free survival rate of 75%.<br /><br />The authors conclude that neoadjuvant therapy containing ICI shows promise in treating locally advanced thymic carcinomas, with patients who respond well to ICI-based therapy having a higher chance of achieving complete resection and better survival rates. They suggest that future clinical trials should investigate the use of neoadjuvant ICI-based therapy in patients with advanced thymic carcinomas.

Asset Subtitle

Xiuxiu Hao

Meta Tag

Speaker Xiuxiu Hao

Topic Thymic Malignancy

Keywords

neoadjuvant immune checkpoint inhibitor

locally advanced thymic malignancies

surgical resection

objective response rate

complete resection rate

perioperative outcomes

progression-free survival

thymic malignancies

thymic carcinomas

clinical trials